High-dose cytarabine (24g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia

Internal Medicine Journal

Volumn 43, Issue 3, 2013, Pages 294-297

  Low, M ^a   Lee, D ^a   Coutsouvelis, J ^a   Patil, S ^a,b   Opat, S ^a,b   Walker, P ^a,b   Schwarer, A ^a,b   Salem, H ^a,b   Avery, S ^a,b   Spencer, A ^a,b   Wei, A ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Acute myeloid leukaemia; Cytarabine; HiDAC; Induction chemotherapy

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT DISEASE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TOLERABILITY; ENTEROCOLITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTICEMIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IDARUBICIN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874379976     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02868.x     Document Type: Article

References (16)

1. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukaemia. Cancer Chemother Rep 1973; 57: 485-488.
2. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP etal. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukaemia: a Southwest Oncology Group study. Blood 1996; 88: 2841-2851.
3. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R etal. Etoposide in acute nonlymphocytic leukaemia. Australian Leukaemia Study Group. Blood 1990; 75: 27-32.
4. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D etal. A randomized study of high-dose cytarabine in induction in acute myeloid leukaemia. Blood 1996; 87: 1710-1717.
5. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T etal. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukaemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488.
6. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM etal. Anthracycline dose intensification in acute myeloid leukaemia. N Engl J Med 2009; 361: 1249-1259.
7. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY etal. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukaemia. Blood 2011; 118: 3832-3841.
8. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N etal. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukaemia: the JALSG AML201 Study. Blood 2011; 117: 2358-2365.
9. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G etal. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
10. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services: National Institutes of Health. National Cancer Institute [cited 2011 June 10]. Available from URL: http://www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
11. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH etal. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
12. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D etal. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukaemia (AML). Leuk Lymphoma 2012; 53: 445-450.
13. Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD etal. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukaemia: a pilot study of the AMLCG. Blood 2009; 113: 3903-3910.
14. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C etal. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027-1036.
15. van der Jagt A, Muirhead J, Seymour JF, Bradstock KF, Paul E, Wei A. Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukaemia 2012; 26: 362-365.
16. Arellano M, Winton E, Pan L, Lima L, Tighiouart M, Bhalla K etal. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukaemia older than 60 years. Cancer 2012; 118: 428-433.